EW vs XPER · P/E 47, rev $1.39B vs rev $493.7M
Edwards Lifesciences Corp (EW) versus Xperi Corp (XPER) — a side-by-side from cached financials, not a winner call.
Edwards Lifesciences Corp (EW) is a medical devices company listed on NYSE.
Xperi Corp (XPER) is a software - application company listed on US.
Latest reported EW revenue for 2024-12-31 was $1.39B. Net income was $385.6M. Revenue was up 2.3% from 2024-09-30 to 2024-12-31. EW currently screens at market cap $49.91B and trailing P/E 46.9.
Latest reported XPER revenue for 2024-12-31 was $493.7M. Net income was -$869.0K. Revenue was down 5.3% from 2023-12-31 to 2024-12-31. XPER currently screens at market cap $367.8M.
EW currently screens at market cap $49.91B and trailing P/E 46.9. XPER currently screens at market cap $367.8M.
Not investment advice. Open the EW and XPER stock pages for the full models.
Not investment advice.